BioCentury | Jul 10, 2020
Finance

Trio of Hong Kong listings raise $865M

Shenzhen Hepalink, the first among a trio of biotechs slated to begin trading on the Hong Kong stock exchange this week, posted a modest first-day dip. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. (SZSE:002399; HKEX:09989), which...
BioCentury | Apr 1, 2020
Distillery Therapeutics

Hyaluronic acid, collagen to prevent intervertebral disc degeneration after herniation

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal An injectable therapy comprising hyaluronic acid and a high-density collagen patch could prevent acute intervertebral disc degeneration after herniation as well as subsequent discectomy. The strategy involves injecting a hexadecyl...
BioCentury | Oct 25, 2019
Tools & Techniques

NASH: how non-invasive biomarkers promise to displace biopsies

Non-invasive biomarkers in NASH are beginning to show where and how they can upstage liver biopsies, with the first impact appearing in patient recruitment. The biggest value will come when they can serve as regulatory...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BioCentury | Sep 7, 2018
Clinical News

EyeGate weighing options for EGP-437 after uveitis failure

EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) said EGP-437 did not show non-inferiority to prednisolone opthalmic solution in a Phase III trial to treat non-infectious anterior segment uveitis. The company is assessing strategic options for the product, which...
BioCentury | Jun 22, 2018
Clinical News

Anika's Cingal misses in Phase III for osteoarthritis knee pain

Anika Therapeutics Inc. (NASDAQ:ANIK) reported that Cingal missed the primary endpoint in the Phase III 16-02 trial to treat pain associated with osteoarthritis (OA) of the knee. Cingal comprises a single injection of sodium hyaluronate...
BioCentury | Jun 20, 2018
Clinical News

Anika's Cingal misses in Phase III for osteoarthritis knee pain

Anika Therapeutics Inc. (NASDAQ:ANIK) was off $9.62 (21%) to $36.50 in after-hours trading Tuesday after reporting that Cingal missed the primary endpoint in the Phase III 16-02 trial to treat pain associated with OA of...
BioCentury | May 15, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Targeting domains Tannic acid conjugates of therapeutic proteins or viral particles could be used for cardiac-specific delivery of therapies for myocardial infarction (MI) and other heart diseases. The method involves conjugating therapeutic proteins or...
BioCentury | May 2, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Polymers Hydrogel-based implants could be used to deliver innate immunity-stimulating agents to help treat solid tumors after surgical resection. The implants consist of biodegradable hyaluronic acid hydrogels cross-linked with polyethylene glycol diacrylate for physical...
BioCentury | Feb 13, 2018
Distillery Techniques

Assays and screens; disease models

TECHNOLOGY: Cellular assays; 3-D models A 3-D culture system that mimics brain tissue could be used to model drug resistance in glioblastoma multiforme and screen therapies. The system involves culturing human GBM cell lines in...
Items per page:
1 - 10 of 483
BioCentury | Jul 10, 2020
Finance

Trio of Hong Kong listings raise $865M

Shenzhen Hepalink, the first among a trio of biotechs slated to begin trading on the Hong Kong stock exchange this week, posted a modest first-day dip. Shenzhen Hepalink Pharmaceutical Group Co. Ltd. (SZSE:002399; HKEX:09989), which...
BioCentury | Apr 1, 2020
Distillery Therapeutics

Hyaluronic acid, collagen to prevent intervertebral disc degeneration after herniation

DISEASE CATEGORY: Musculoskeletal INDICATION: Musculoskeletal An injectable therapy comprising hyaluronic acid and a high-density collagen patch could prevent acute intervertebral disc degeneration after herniation as well as subsequent discectomy. The strategy involves injecting a hexadecyl...
BioCentury | Oct 25, 2019
Tools & Techniques

NASH: how non-invasive biomarkers promise to displace biopsies

Non-invasive biomarkers in NASH are beginning to show where and how they can upstage liver biopsies, with the first impact appearing in patient recruitment. The biggest value will come when they can serve as regulatory...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BioCentury | Sep 7, 2018
Clinical News

EyeGate weighing options for EGP-437 after uveitis failure

EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) said EGP-437 did not show non-inferiority to prednisolone opthalmic solution in a Phase III trial to treat non-infectious anterior segment uveitis. The company is assessing strategic options for the product, which...
BioCentury | Jun 22, 2018
Clinical News

Anika's Cingal misses in Phase III for osteoarthritis knee pain

Anika Therapeutics Inc. (NASDAQ:ANIK) reported that Cingal missed the primary endpoint in the Phase III 16-02 trial to treat pain associated with osteoarthritis (OA) of the knee. Cingal comprises a single injection of sodium hyaluronate...
BioCentury | Jun 20, 2018
Clinical News

Anika's Cingal misses in Phase III for osteoarthritis knee pain

Anika Therapeutics Inc. (NASDAQ:ANIK) was off $9.62 (21%) to $36.50 in after-hours trading Tuesday after reporting that Cingal missed the primary endpoint in the Phase III 16-02 trial to treat pain associated with OA of...
BioCentury | May 15, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Targeting domains Tannic acid conjugates of therapeutic proteins or viral particles could be used for cardiac-specific delivery of therapies for myocardial infarction (MI) and other heart diseases. The method involves conjugating therapeutic proteins or...
BioCentury | May 2, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Polymers Hydrogel-based implants could be used to deliver innate immunity-stimulating agents to help treat solid tumors after surgical resection. The implants consist of biodegradable hyaluronic acid hydrogels cross-linked with polyethylene glycol diacrylate for physical...
BioCentury | Feb 13, 2018
Distillery Techniques

Assays and screens; disease models

TECHNOLOGY: Cellular assays; 3-D models A 3-D culture system that mimics brain tissue could be used to model drug resistance in glioblastoma multiforme and screen therapies. The system involves culturing human GBM cell lines in...
Items per page:
1 - 10 of 483